Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Deep-amplicon sequencing of the complete beta-tubulin gene in Trichuris trichiura before and after albendazole treatment

  • Gandasegui, Javier|||0000-0001-5519-738X
  • Grau-Pujol, Berta|||0000-0002-7320-0965
  • Novela, Valdemiro
  • Muchisse, Osvaldo
  • Cambra-Pellejà, Maria
  • Cossa, Anélsio
  • Jamine, José Carlos
  • Sacoor, Charfudin
  • Brienen, Eric A T.
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • Van Lieshout, Lissete
  • Martínez-Valladares, María
  • Paredes, Roger|||0000-0002-6553-691X
  • Muñoz Gutiérrez, José|||0000-0002-0945-1735
  • Doyle, Stephen R.|||0000-0001-9167-7532
Concerns about the emergence of benzimidazole resistance in soil-transmitted helminths (STH) infections, particularly against Trichuris trichiura, have arisen. Previous studies of veterinary nematodes have linked benzimidazole resistance to single-nucleotide polymorphisms (SNPs) at three specific codons in the beta-tubulin gene, but similar associations in STH have not been consistently observed. In this work, we screened the complete beta-tubulin gene previously linked to benzimidazole resistance in T. trichiura by deep-amplicon sequencing to identify genetic variants and associate levels of diversity with drug response to albendazole. We used 99 DNA samples extracted from T. trichiura pooled eggs, previously semi-purified from human stool samples collected in Manhiça district, Mozambique. We obtained a set of 39 amplicons of the complete gene by subjecting the pooled eggs to long-read PCR and subsequently sequencing them. Of those amplicons, 22 and 17 were obtained from stool samples collected before, and 21 days after albendazole treatment, respectively. We observed genetic variation across the whole gene sequence, in both exons and introns; however, none were associated with the previously proposed resistance-associated SNPs, and none were predicted to significantly affect protein function. No significant differences in genetic diversity were observed between pre- and post-treatment samples. Using publicly available genome-wide data, we also analysed a second beta-tubulin isotype in the T. trichiura genome. We focused on detecting the canonical SNPs and assessing for signatures of genetic selection around this second isotype gene. This analysis did not reveal evidence supporting this second isotype's role in anthelmintic resistance. Despite the limitations of our study, such as a small sample size, particularly paired pre- and post-treatment samples (n = 6), or a restricted geographical area, we found no evidence linking either of the two beta-tubulin genes to benzimidazole resistance in T. trichiura, suggesting that genetic markers of drug resistance likely exist outside the beta-tubulin genes.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

pLDH to identify severity in imported malaria: Implementing smartphone video analysis for rapid clinical decision-making

  • Pedreira-Rincón, Julia
  • Balerdi-Sarasola, Leire
  • Villanueva Benito, Guillermo
  • Fleitas, Pedro E.
  • Jiménez, Alfons
  • Mayor, Alfredo
  • Muñoz, José
  • Subirá, Carme
  • Alvarez-Martinez, Miriam J.
  • Petrone, Paula M.
  • Camprubí-Ferrer, Daniel
  • Parolo, Claudio
Malaria is the main parasitic disease-causing death in endemic and non-endemic regions. Imported malaria cases face an elevated risk of severe disease, but non-specific clinical presentations and limited clinician experience often delay diagnosis, prognosis and treatment. Quantification of parasite biomarkers by lateral flow assays (LFAs) could address this challenge. We conducted a retrospective cohort study of patients with imported Plasmodium falciparum malaria and non-malarial fevers. Using a bead-based multiplex immunoassay and commercial LFAs, we evaluated the diagnostic and severity assessment capabilities of two parasite biomarkers: Plasmodium falciparum histidine-rich protein-2 (PfHRP2) and pan-specific lactate dehydrogenase (pan-pLDH). To improve the speed and objectivity of LFA interpretation, we used smartphone-based image- and video-analysis. The bead-based immunoassay showcased an excellent diagnostic performance for PfHRP2 and pan-pLDH, while revealing PfHRP2 and pan-pLDH as promising severity biomarkers. On LFAs, PfHRP2 maintained perfect diagnostic accuracy, compared to pan-pLDH. Notably, pan-pLDH excelled in identifying severe malaria cases, outperforming PfHRP2. Smartphone-based video-analysis reduced testing time to under 6 min and maintained pan-pLDH's performance in detecting severe malaria. Our study underscores the potential of pan-pLDH as a valuable biomarker for severity assessment in imported Plasmodium falciparum malaria cases, particularly in non-endemic settings where rapid clinical decisions are critical., The ISGlobal authors acknowledge support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research was supported by CIBER -Consorcio Centro de Investigación Biomédica en Red - CB21/13/00112. Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. With the support of AGAUR-FI ajuts (2024 FI-1 00737) Joan Oró de la secretaria d'Universitats i Recerca del Departament de Recerca i Universitats de la Generalitat de Catalunya i del Fons Europeu Social Plus. They also acknowledge support from the Spanish Ministry of Science and Innovation through the program PID2020-116770RJ-I00 and CPP2021-008658. C.P. acknowledges support from the Hospital Clínic of Barcelona, the Caixa Research Institute Innovation Hub and Caixa Impulse project CI24- 10491 and from the Spanish Ministry of Science through the Ramón y Cajal grant no. RYC2022036743-I. A.M. acknowledges support from AGAUR (Generalitat de Catalunya, 2021 SGR 01517). P.P acknowledges her AI4S fellowship within the “Generación D” initiative by Red.es, Ministerio para la Transformación Digital y de la Función Pública, for talent attraction (C005/24-ED CV1), funded by NextGenerationEU through PRTR. G. V. acknowledges support funded by the European Union-NextGenerationEU, in the Investigo Program for the hiring of young job demanders in the realization of research and innovation initiatives (INVESTIGO 2022) (AGAUR- ref. BDNS 608313 ), expedient 2022 INV-1 00046 Code 100046TC8. We thank the entire CEK “support” team for their assistance, with special appreciation to Cristina Canaleta, Laura Muñoz, Laura Puyol, and Diana Barrios. We also acknowledge the contributions of other research groups from ISGlobal and IDIBAPS. Additionally, we extend our gratitude to all the healthcare personnel of the Travel Medicine Clinic of the Hospital Clínic of Barcelona for their support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Harnessing bioluminescent bacteria to develop an enzymatic-free enzyme-linked immunosorbent assay for the detection of clinically relevant biomarkers

  • Hu, Liming
  • Rossetti, Marianna
  • Bergua, José Francisco
  • Parolo, Claudio
  • Álvarez-Diduk, Ruslan
  • Rivas, Lourdes
  • Idili, Andrea
  • Merkoçi, Arben
Enzyme-linked immunosorbent assay (ELISA) is the gold standard technique for measuring protein biomarkers due to its high sensitivity, specificity, and throughput. Despite its success, continuous advancements in ELISA and immunoassay formats are crucial to meet evolving global challenges and to address new analytical needs in diverse applications. To expand the capabilities and applications of immunoassays, we introduce a novel ELISA-like assay that we call Bioluminescent-bacteria-linked immunosorbent assay (BBLISA). BBLISA is an enzyme-free assay that utilizes the inner filter effect between the bioluminescent bacteriaAllivibrio fischeriand metallic nanoparticles (gold nanoparticles and gold iridium oxide nanoflowers) as molecular absorbers. Functionalizing these nanoparticles with antibodies induces their accumulation in wells upon binding to molecular targets, forming the classical immune-sandwich complex. Thanks to their ability to adsorb the light emitted by the bacteria, the nanoparticles can suppress the bioluminescence signal, allowing the rapid quantification of the target. To demonstrate the bioanalytical properties of the novel immunoassay platform, as a proof of principle, we detected two clinically relevant biomarkers (human immunoglobulin G and SARS-CoV-2 nucleoprotein) in human serum, achieving the same sensitivity and precision as the classic ELISA. We believe that BBLISA can be a promising alternative to the standard ELISA techniques, offering potential advancements in biomarker detection and analysis by combining nanomaterials with a low-cost, portable bioluminescent platform., We acknowledge Consejo Superior de Investigaciones Científicas (CSIC) for the project “COVID19-122”. TheMICROB-PREDICT project has received funding from theEuropean Union’s Horizon 2020 research and innovationprogramme under grant agreement no 881603. ICN2 is fundedby CERCA programme / Generalitat de Catalunya, and issupported by the Severo Ochoa Centres of Excellenceprogramme, Grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. L.H. acknowledges ChinaScholarship Council (no. 201808360196) and acknowledges Universitat Autonoma de Barcelona (UAB) for the possibilityof performing this work inside the framework of Biotechnology Ph.D. Programme. M.R. acknowledges the MSCA projectfunded the European Union’s Horizon 2020 research andinnovation programme under the Marie Sklodowska-Curiegrant agreement no 101029884. C.P. acknowledges supportfrom the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033, support from the Generalitat deCatalunya through the CERCA Program and support from theSpanish Ministry of Science and Innovation through theprogram PID2020-116770RJ-I00 and CPP2021-008658. TheICN2 is funded by the CERCA programme / Generalitat deCatalunya. The ICN2 is A.M. acknowledge Departament deRecerca i Universitats of Generalitat de Catalunya for the grant 2021 SGR 01464. This project has received funding from the European Union’s Horizon Europe − the Framework Programme for Research and Innovation (2021-2027) undergrant agreement No 101120706., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001214-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2018-000806-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deep-amplicon sequencing of the complete beta-tubulin gene in Trichuris trichiura before and after albendazole treatment

  • Gandasegui, Javier
  • Grau-Pujol, Berta
  • Novela, Valdemiro
  • Muchisse, Osvaldo
  • Cambra-Pellejà, Maria
  • Cossa, Anélsio
  • Jamine, José Carlos
  • Sacoor, Charfudin
  • Brienen, Eric A.T.
  • Catala-Moll, Francesc
  • van Lieshout, Lisette
  • Martínez Valladares, María
  • Paredes, Roger
  • Muñoz, José
  • Doyle, Stephen R
8 páginas, 2 figuras, 1 tabla., Concerns about the emergence of benzimidazole resistance in soil-transmitted helminths (STH) infections, particularly against Trichuris trichiura, have arisen. Previous studies of veterinary nematodes have linked benzimidazole resistance to single-nucleotide polymorphisms (SNPs) at three specific codons in the beta-tubulin gene, but similar associations in STH have not been consistently observed. In this work, we screened the complete beta-tubulin gene previously linked to benzimidazole resistance in T. trichiura by deep-amplicon sequencing to identify genetic variants and associate levels of diversity with drug response to albendazole. We used 99 DNA samples extracted from T. trichiura pooled eggs, previously semi-purified from human stool samples collected in Manhiça district, Mozambique. We obtained a set of 39 amplicons of the complete gene by subjecting the pooled eggs to long-read PCR and subsequently sequencing them. Of those amplicons, 22 and 17 were obtained from stool samples collected before, and 21 days after albendazole treatment, respectively. We observed genetic variation across the whole gene sequence, in both exons and introns; however, none were associated with the previously proposed resistance-associated SNPs, and none were predicted to significantly affect protein function. No significant differences in genetic diversity were observed between pre- and post-treatment samples. Using publicly available genome-wide data, we also analysed a second beta-tubulin isotype in the T. trichiura genome. We focused on detecting the canonical SNPs and assessing for signatures of genetic selection around this second isotype gene. This analysis did not reveal evidence supporting this second isotype's role in anthelmintic resistance. Despite the limitations of our study, such as a small sample size, particularly paired pre- and post-treatment samples (n = 6), or a restricted geographical area, we found no evidence linking either of the two beta-tubulin genes to benzimidazole resistance in T. trichiura, suggesting that genetic markers of drug resistance likely exist outside the beta-tubulin genes., The authors are grateful to this study's participants, community leaders, and local government authorities for their unconditional support and collaboration. Special thanks to all CISM's staff, particularly the Demography and Social Sciences department, for their indispensable assistance and to those involved in data collection and laboratory testing. This research was conducted with the support of the Stopping Transmission Of intestinal Parasites (STOP) consortium funded by the EDCTP2 programme (grant number RIA2017NCT-1845 STOP), Horizon 2020European Union Funding for Research and Innovation, and Mundo Sano Foundation. The ISGlobal authors acknowledge support from the Spanish Ministry of Science and Innovation and State Research Agency through the ‘Centro de Excelencia Severo Ochoa 2019–2023’ Program (CEX2018-000806-S), CIBER-Consorcio Centro de Investigación Biomédica en Red-(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea and support from the Generalitat de Catalunya through the CERCA Program. CISM receives core funding from the “Agencia Española de Cooperación Internacional para el Desarollo” (AECID). MCP discloses support from: 'Pla de Doctorats Industrials' (DIN2022) of Departament de Recerca i Universitats de la Generalitat de Catalunya; ‘Ayudas a proyectos de colaboración público-privada’ (CPP2022-009773) funded by the MCIN/AEI/10.13039/501100011033 and the European Union ‘NextGenerationEU’/PRTR; and ‘Ayudas para la formación de doctores en empresas « Doctorados Industriales»’ (DIN2022-012602) funded by MCIN/AEI/10.13039/501100011033. JM also acknowledges support from the Hospital Clinic of Barcelona and the Spanish Ministry of Science and Innovation through the programs PID2020-116770RJ-I00 and CPP2021-008658. SRD is supported by a UKRI Future Leaders Fellowship (MR/T020733/1), Wellcome via core funding of the Wellcome Sanger Institute [220540/Z/20/A], and a grant (101103089). For the purpose of Open Access, the authors have applied a CC BY public copyright Licence to any Author Accepted Manuscript version arising from this submission., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

pLDH to identify severity in imported malaria: Implementing smartphone video analysis for rapid clinical decision-making

  • Pedreira-Rincón, Julia
  • Balerdi-Sarasola, Leire
  • Villanueva Benito, Guillermo
  • Fleitas, Pedro E.
  • Jiménez, Alfons
  • Mayor, Alfredo
  • Muñoz, José
  • Subirá, Carme
  • Alvarez-Martinez, Miriam J.
  • Petrone, Paula M.
  • Camprubí-Ferrer, Daniel
  • Parolo, Claudio
Malaria is the main parasitic disease-causing death in endemic and non-endemic regions. Imported malaria cases face an elevated risk of severe disease, but non-specific clinical presentations and limited clinician experience often delay diagnosis, prognosis and treatment. Quantification of parasite biomarkers by lateral flow assays (LFAs) could address this challenge. We conducted a retrospective cohort study of patients with imported Plasmodium falciparum malaria and non-malarial fevers. Using a bead-based multiplex immunoassay and commercial LFAs, we evaluated the diagnostic and severity assessment capabilities of two parasite biomarkers: Plasmodium falciparum histidine-rich protein-2 (PfHRP2) and pan-specific lactate dehydrogenase (pan-pLDH). To improve the speed and objectivity of LFA interpretation, we used smartphone-based image- and video-analysis. The bead-based immunoassay showcased an excellent diagnostic performance for PfHRP2 and pan-pLDH, while revealing PfHRP2 and pan-pLDH as promising severity biomarkers. On LFAs, PfHRP2 maintained perfect diagnostic accuracy, compared to pan-pLDH. Notably, pan-pLDH excelled in identifying severe malaria cases, outperforming PfHRP2. Smartphone-based video-analysis reduced testing time to under 6 min and maintained pan-pLDH's performance in detecting severe malaria. Our study underscores the potential of pan-pLDH as a valuable biomarker for severity assessment in imported Plasmodium falciparum malaria cases, particularly in non-endemic settings where rapid clinical decisions are critical., The ISGlobal authors acknowledge support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research was supported by CIBER -Consorcio Centro de Investigación Biomédica en Red - CB21/13/00112. Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. With the support of AGAUR-FI ajuts (2024 FI-1 00737) Joan Oró de la secretaria d'Universitats i Recerca del Departament de Recerca i Universitats de la Generalitat de Catalunya i del Fons Europeu Social Plus. They also acknowledge support from the Spanish Ministry of Science and Innovation through the program PID2020-116770RJ-I00 and CPP2021-008658. C.P. acknowledges support from the Hospital Clínic of Barcelona, the Caixa Research Institute Innovation Hub and Caixa Impulse project CI24- 10491 and from the Spanish Ministry of Science through the Ramón y Cajal grant no. RYC2022036743-I. A.M. acknowledges support from AGAUR (Generalitat de Catalunya, 2021 SGR 01517). P.P acknowledges her AI4S fellowship within the “Generación D” initiative by Red.es, Ministerio para la Transformación Digital y de la Función Pública, for talent attraction (C005/24-ED CV1), funded by NextGenerationEU through PRTR. G. V. acknowledges support funded by the European Union-NextGenerationEU, in the Investigo Program for the hiring of young job demanders in the realization of research and innovation initiatives (INVESTIGO 2022) (AGAUR- ref. BDNS 608313 ), expedient 2022 INV-1 00046 Code 100046TC8. We thank the entire CEK “support” team for their assistance, with special appreciation to Cristina Canaleta, Laura Muñoz, Laura Puyol, and Diana Barrios. We also acknowledge the contributions of other research groups from ISGlobal and IDIBAPS. Additionally, we extend our gratitude to all the healthcare personnel of the Travel Medicine Clinic of the Hospital Clínic of Barcelona for their support.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Harnessing Bioluminescent Bacteria to Develop an Enzymatic-free Enzyme-linked immunosorbent assay for the Detection of Clinically Relevant Biomarkers

  • Hu, Liming|||0000-0002-8666-9287
  • Rossetti, Marianna|||0000-0001-5711-1287
  • Bergua Canudo, José Francisco|||0000-0002-5969-193X
  • Parolo, Claudio|||0000-0001-9481-4408
  • Álvarez Diduk, Ruslan|||0000-0002-9876-1574
  • Rivas, Lourdes|||0000-0002-1510-5927
  • Idili, Andrea|||0000-0002-6004-270X
  • Merkoçi, Arben|||0000-0003-2486-8085
Enzyme-linked immunosorbent assay (ELISA) is the gold standard technique for measuring protein biomarkers due to its high sensitivity, specificity, and throughput. Despite its success, continuous advancements in ELISA and immunoassay formats are crucial to meet evolving global challenges and to address new analytical needs in diverse applications. To expand the capabilities and applications of immunoassays, we introduce a novel ELISA-like assay that we call Bioluminescent-bacteria-linked immunosorbent assay (BBLISA). BBLISA is an enzyme-free assay that utilizes the inner filter effect between the bioluminescent bacteriaAllivibrio fischeriand metallic nanoparticles (gold nanoparticles and gold iridium oxide nanoflowers) as molecular absorbers. Functionalizing these nanoparticles with antibodies induces their accumulation in wells upon binding to molecular targets, forming the classical immune-sandwich complex. Thanks to their ability to adsorb the light emitted by the bacteria, the nanoparticles can suppress the bioluminescence signal, allowing the rapid quantification of the target. To demonstrate the bioanalytical properties of the novel immunoassay platform, as a proof of principle, we detected two clinically relevant biomarkers (human immunoglobulin G and SARS-CoV-2 nucleoprotein) in human serum, achieving the same sensitivity and precision as the classic ELISA. We believe that BBLISA can be a promising alternative to the standard ELISA techniques, offering potential advancements in biomarker detection and analysis by combining nanomaterials with a low-cost, portable bioluminescent platform.